Epithelial Dysmetabolism and Kidney Fibrosis in ANCA Vasculitis
Official title: Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
Run by Assistance Publique - Hôpitaux de Paris · NCT07010250 · Data updated 2026-11-12
This study tests whether alterations in tubulo-interstitial metabolism relate to how quickly kidney function deteriorates in people with ANCA-associated vasculitis compared to other nephropathies.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 146 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris) |
| Status | Recruiting |
| Started | November 3, 2025 |
| Main results expected | November 2, 2029 |
| Study ends | November 2, 2029 |
| Registry record updated | June 30, 2026 |
| Trial ID | NCT07010250 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 to 90 with a biopsy-indicated kidney condition and French health insurance who give consent.
✕Probably not a fit
Patients with conditions not showing a link between tubulo-interstitial metabolism and progression may not benefit from this observational work.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational effort compares patients with ANCA-associated vasculitis and rapidly progressive glomerulonephritis to six other nephropathy groups, including extramembranous glomerulopathy and minimal change disease, to explore links between tubulo-interstitial metabolism and renal decline. Participants undergo initial diagnostic procedures and are categorized by biopsy-confirmed nephropathy; no interventional treatment is specified. The study design emphasizes natural history and biomarker correlations across diverse nephropathies to understand disease mechanisms. Eligible adults with renal biopsy indications and French health insurance coverage are enrolled, with exclusions for transplant, dialysis, pregnancy, legal guardianship, or concurrent interventional studies.
Why it matters
Potential benefit: If successful, findings could improve understanding of kidney disease progression across nephropathies and inform future targeted therapies.
How similar studies have gone: Prior research has explored nephropathy heterogeneity and metabolism but this exact comparative approach across multiple nephropathies is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with an indication for initial diagnostic PBR on native kidney * 18 ans ≥ Age ≤ 90 ans * Affiliation to french health insurance * Patient having given consent For the ANCA vasculitis group: • Diagnosis of ANCA vasculitis retained on renal biopsy with ANCA anti-proteinase 3 (PR3) or ANCA anti-myeloperoxidase (MPO) For the control groups: • Diagnosis retained after the renal biopsy * Interstitial Nephritis * Or glomerular nephropathy such as minimal change nephropathy * Or Segmental hyalinosis in itscollapsing form * Or Extramembranous Glomerulopathy, * Or glomerulopathy with mesangial IgA deposits * Or diabetic nephropathy. Exclusion Criteria: * Kidney transplant patient * Patient on dialysis (hemodialysis or peritoneal dialysis) * Patient under legal protection, guardianship or curatorship * Pregnancy or breastfeeding * Enrollement in an interventional study except studies relating to ANCA vasculitis and nephropathy with mesangial IgA deposits.
Where it's running
-
Georges-Pompidou European Hospital, AP-HP
Paris, France Recruiting
Study contacts
- Principal investigator: Marine LIVROZET — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Maxime BRUSSIEUX
- Email: maxime.brussieux@aphp.fr
- Phone: +33 1 44 84 17 89
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Anti-CD19/BCMA universal CAR-T (RD06-05) for autoimmune diseases
This early-phase test gives a universal CAR-T therapy (RD06-05) that targets CD19 and BCMA to adults with autoimmune diseases such as SLE/lupus nephritis, ANCA-associated vasculitis, and anti-GBM disease.
-
JADE101 in IgA Nephropathy: a Phase 2 test in adults
This Phase 2 open-label study tests JADE101 in adults with IgA nephropathy to see how safe it is and how well it works when added to standard care.
-
Atrasentan for pediatric primary IgA nephropathy
This study tests whether atrasentan can help children and teens with primary IgA nephropathy reduce protein in urine.
-
Transformative 2.0 for diabetic kidney disease
This project will try to see if adults with diabetic kidney disease who take SGLT2 diabetes medicines have different biological patterns in archived kidney tissue than similar people who do not take these medicines.
-
BCT301 CAR-iT cell therapy for hard-to-treat autoimmune diseases
This early‑phase study tests whether off-the-shelf BCT301 CAR-iT cells can be given safely to adults with refractory autoimmune diseases to see if they can be tolerated and what dose works best.
-
Characterization of Autoreactive B Cells in Autoimmune Diseases and Immune Deficiencies
Researchers are testing to see how autoreactive B cells behave in people with autoimmune diseases or immune deficiencies to better understand how these cells may contribute to disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.